Case #27 – Mac Degen in 2010

Mac Degen in 2010 – Page 53 of 62

Macular Protective Pigment Density Research has focused on further analysis of the pigment, its relationship to AMD, its absorption, transport and metabolism. Research suggests an association between a particular type of macular degeneration and a diet low in lutein and zeaxanthin; the evidence noting the protective role of macular protective pigment. Decreased

Mac Degen in 2010 – Page 53 of 622021-03-03T20:59:30+00:00

Mac Degen in 2010 – Page 52 of 62

The macular pigment optical density can also be measured with ZeaVision's Eye-Q AMD Risk Management program which utilizes the QuantifEYE® device. Macular Pigment Optical Density measurement

Mac Degen in 2010 – Page 52 of 622021-03-03T20:59:36+00:00

Mac Degen in 2010 – Page 51 of 62

Macuscope The macular carotenoids are architecturally positioned for maximal antioxidant and light filtration activity. In addition to cellular protection, the macular protective pigment (MPP) is thought to enhance vision by decreasing chromatic aberration and removing atmospheric blue haze. The macula is the only place in the human body where the carotenoids lutein and

Mac Degen in 2010 – Page 51 of 622021-03-03T20:59:44+00:00

Mac Degen in 2010 – Page 50 of 62

Macuscope The macular protective pigment density (MPPD) refers to macular protective pigment layer composed of the carotenoids: lutein, zeaxanthin and meso-zeaxanthin in the macula, which is anterior to, and independent of the melanin rich retinal pigment epithelium Although the exact mechanism of AMD has yet to be determined, two very strong theories

Mac Degen in 2010 – Page 50 of 622021-03-03T20:59:55+00:00

Mac Degen in 2010 – Page 49 of 62

Macula Risk® Recommendations                                           All specialties Screen patients over 65 yrs with large drusen (over 125µ); Refer 'high risk' to RS for a base-line exam and new medical record;

Mac Degen in 2010 – Page 49 of 622021-03-03T21:00:03+00:00

Mac Degen in 2010 – Page 48 of 62

Macula Risk® Patient Report Sample The patient's results are a comprehensive 6 page report including: medical results, genetic counseling, how genetic inheritance affects AMD, and non-genetic risk factors associated with AMD.

Mac Degen in 2010 – Page 48 of 622021-03-03T21:00:10+00:00

Mac Degen in 2010 – Page 47 of 62

Macula Risk® Score Risk of Progressing to Advanced AMD by 80 Years of Age The Macula Risk® results place the patient in 1 of 5 different categories which correlates to the patient's risk of developing AMD that progresses to vision loss.

Mac Degen in 2010 – Page 47 of 622021-03-03T21:00:18+00:00

Mac Degen in 2010 – Page 45 of 62

AMD Runs in Familes AMD runs in families. Individuals with a family history of Macular Degeneration are 4 times more likely to develop AMD with vision loss as they age. The incidence of AMD in the general population is 10%. One in 10 people will lose vision from AMD by the time they are 80.

Mac Degen in 2010 – Page 45 of 622021-03-03T21:00:35+00:00

Mac Degen in 2010 – Page 44 of 62

Age-related Macular Degeneration or AMD is predominantly a genetic disease. Macula Risk is a DNA test that is intended to identify individuals who have the disease causing genes. These individuals are at increased risk of vision loss as they age. There are disease management strategies that can minimize the impact of AMD

Mac Degen in 2010 – Page 44 of 622021-03-03T21:00:42+00:00